Opinion|Videos|November 20, 2026

HPV Testing With p16 and Confirmatory Assays

Ross Merkin, MD, outlines 2 approaches to human papillomavirus (HPV) testing in head and neck squamous cell carcinoma: surrogate testing and tests that confirm HPV infection.

Ross Merkin, MD, outlines 2 approaches to human papillomavirus (HPV) testing in head and neck squamous cell carcinoma: surrogate testing and tests that confirm HPV infection. p16 immunohistochemistry is a readily available surrogate; however, p16 can also be upregulated through HPV-independent pathways, which supports confirmatory in situ hybridization or polymerase chain reaction testing. Dr. Merkin reviews College of American Pathologists guidance published about a year earlier. For a classic oropharyngeal presentation, such as a nonkeratinizing base-of-tongue tumor on biopsy, p16 testing alone suffices, while most other scenarios call for p16 screening followed by confirmatory HPV testing. He notes that the distinction matters because HPV-driven and non-HPV-driven tumors are biologically different diseases, and published data show that patients with discordant p16 and HPV results have a prognosis between those of double-positive and double-negative patients. Will Ince, MRCP, FRCR, says clinicians should test all patients properly for HPV and calls reliance on p16 alone potentially fraught.


Related to this article